Vancouver, Wash. biotech company Absci files to go public
July 1, 2021 at 8:36 am
Absci CEO and founder Sean McClain. (Absci Photo)
Absci, a Vancouver, Wash.-based company developing technologies to accelerate the process of drug discovery, announced today that it plans to go public via an IPO. The company’s platform is built to design and generate protein-based drug candidates and help screen them for optimal functioning.
The announcement follows a string of acquisitions and funding rounds for the company. This month the company acquired the synthetic biology company Totient, following its January acquisition of Denovium, a small deep learning startup capable of analyzing the function and behavior of proteins.